Dirk-Jan Slebos

3 weeks ago | publications.ersnet.org | Dirk-Jan Slebos |Jorine Hartman

IntroductionCOPD is a major cause of chronic morbidity and mortality worldwide [1]. The emphysema phenotype of COPD is characterised by air trapping and hyperinflation, driven by the loss of elastic recoil and the subsequent increase in airflow resistance, resulting from the destruction of lung parenchyma [2].

Nov 18, 2024 | publications.ersnet.org | Dirk-Jan Slebos |Karin Klooster |Simon D. Pouwels |Jorine Hartman

IntroductionCOPD is the third leading cause of death worldwide and is responsible for ∼6% of the total number of global deaths according to the World Health Organization [1]. COPD is a complex and heterogeneous disease, not only characterised by chronic airflow limitation, but also by the frequent occurrence of comorbidities. For example, Vanfleteren et al.

Feb 17, 2024 | resmedjournal.com | Rein Posthuma |Jorine Hartman |Martijn A. Spruit |Dirk-Jan Slebos |Lowie E.G.W. Vanfleteren |Anouk W. Vaes

Patients with advanced emphysema eligible for bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV) are characterized by severe static lung hyperinflation, which can be considered a treatable trait. Other treatable traits (TTs), which are assumed to be present in this highly selected patient group, have not been studied in detail nor how they may affect health-related quality of life (HRQL).